What is the primary objective of PIPL?

PIPL's primary objective is to protect natural persons' personal information rights while regulating handling activities to promote reasonable data use. Enacted August 20, 2021, and effective November 1, 2021, the law's 74 articles establish principles of lawfulness, necessity, minimization, transparency, accuracy, integrity, confidentiality, and accountability (Article 5). It safeguards dignity, safety, and property against risks from sensitive personal information (SPI), including biometrics, health data, and minors' data under 14.

Who is legally or professionally required to comply with PIPL?

PIPL requires compliance from all personal information handlers processing data of natural persons within China, with extraterritorial reach to foreign entities targeting Chinese individuals. This includes domestic and overseas organizations providing products/services to or analyzing behaviors of persons in China (Article 3). Handlers must appoint a China representative if abroad (Article 53); large-scale processors (>1 million individuals) designate a Personal Information Protection Officer (PIPO) and report to authorities.

Does PIPL require an external audit or third-party certification?

PIPL mandates internal compliance audits but requires third-party certification only for specific cross-border transfers. Handlers processing >1 million individuals' data conduct audits at least annually; others conduct audits at least every two years. Certification is optional for transfers (100,000–1M PI or 1M PI or >10K SPI (2024 Provisions). No general external audit mandate exists.

How often should an assessment for PIPL be performed?

PIPL requires Personal Information Protection Impact Assessments (PIPIAs) before high-risk processing, with regular internal audits ongoing. PIPIAs precede SPI handling, automated decision-making, transfers, or major-impact activities (Article 55), retained 3 years. Audits occur at least annually for >1 million individuals, and biennially for others; routinely for all handlers per governance rules (Article 51).

What are the consequences of non-compliance with PIPL?

Non-compliance with PIPL incurs fines up to RMB 50 million or 5% of prior-year global revenue for grave violations, plus personal liability. Penalties include corrections, business suspension, license revocation (Article 66). Responsible executives face RMB 1M fines and management bans. Civil suits shift proof burden to handlers; criminal liability for severe cases like SPI trafficking.

An PIPL be mapped to other international frameworks?

Yes, PIPL maps to frameworks like GDPR via shared principles but differs in consent primacy, lacking legitimate interests basis. Similarities include minimization, rights (access, deletion), impact assessments, and fines tied to revenue. Divergences: stricter SPI (risk-of-harm test), cross-border thresholds (>1M PI), no broad legitimate interests, national security ties.

What is the first step to begin implementing PIPL?

The first step for PIPL implementation is conducting a comprehensive gap analysis and data mapping. Inventory PI flows, classify SPI, map purposes/bases/retention (Phase 1 framework). Secure executive sponsorship, appoint program lead, and build processing register to identify remediation priorities.

What is the primary objective of FDA 21 CFR Part 11?

The primary objective of FDA 21 CFR Part 11 is to establish criteria under which the FDA considers electronic records and electronic signatures trustworthy, reliable, and equivalent to paper records and handwritten signatures (§11.1(a)). This equivalency enables electronic technology use while ensuring authenticity, integrity, confidentiality (when appropriate), and non-repudiation through controls in closed (§11.10) and open (§11.30) systems, plus signature requirements (§§11.50–11.300).

Who is legally or professionally required to comply with FDA 21 CFR Part 11?

FDA 21 CFR Part 11 applies to organizations using electronic records created, modified, maintained, archived, retrieved, or transmitted under predicate rules, or relied upon for regulated activities (§11.1(b)). This includes life sciences firms (pharma, biotech, devices) maintaining predicate-required records electronically in lieu of paper, submitting accepted electronic records to FDA, or using legally binding electronic signatures. Paper-reliant systems are generally exempt if not relied upon.

Does FDA 21 CFR Part 11 require an external audit or third-party certification?

No, FDA 21 CFR Part 11 does not require external audits or third-party certification. Compliance is demonstrated through internal controls, validation, SOPs, and inspection readiness (§11.1(e)), with systems and documentation available for FDA review. FDA's 2003 guidance emphasizes risk-based approaches without mandating external validation.

How often should an assessment for FDA 21 CFR Part 11 be performed?

FDA 21 CFR Part 11 does not prescribe a fixed frequency for assessments; they must occur via change control, periodic reviews, and risk-based validation lifecycles. Ongoing monitoring includes operational checks (§11.10(f)), documentation controls (§11.10(k)), and predicate rule alignment, with reassessments triggered by system changes, inspections, or risk updates per 2003 guidance.

What are the consequences of non-compliance with FDA 21 CFR Part 11?

Non-compliance with FDA 21 CFR Part 11 results in FDA enforcement actions including Form 483 observations, warning letters, product holds, and fines, as predicate rules remain fully enforceable. The 2003 guidance notes continued enforcement of access controls, checks, training, signatures, and documentation failures, often leading to data integrity violations and operational disruptions.

Can FDA 21 CFR Part 11 be mapped to other international frameworks?

Yes, FDA 21 CFR Part 11 controls can be mapped to frameworks like EU Annex 11 for electronic records/signatures, focusing on shared principles of validation, audit trails, access, and integrity. However, Part 11's narrow scope and enforcement discretion require tailored alignment without assuming equivalence.

What is the first step to begin implementing FDA 21 CFR Part 11?

The first step to implement FDA 21 CFR Part 11 is to establish a formal applicability framework mapping predicate rules to records and assessing business reliance on electronic versions. Document scope decisions in SOPs per 2003 guidance, classifying systems as closed/open and prioritizing high-risk controls like access (§11.10(d)) and signatures (§11.100).

Standards Comparison

PIPL vs FDA 21 CFR Part 11

PIPL

Mandatory

2021

China's comprehensive regulation for personal data protection

FDA 21 CFR Part 11

Mandatory

1997

FDA regulation for trustworthy electronic records and signatures

Quick Verdict

PIPL protects personal data for China operations with consent and transfer rules, while FDA 21 CFR Part 11 ensures electronic records' integrity for life sciences. Companies adopt PIPL for market access, Part 11 for regulatory equivalence and inspections.

Data Privacy

PIPL

Personal Information Protection Law (PIPL)

Cost

€€€€

Complexity

Medium

Implementation Time

6-12 months

Key Features

Extraterritorial scope for foreign entities targeting China
Explicit separate consent required for sensitive data
Cross-border transfers via SCCs or security assessments
Fines up to 5% of annual revenue possible
Minors under 14 data classified as sensitive

Electronic Records

FDA 21 CFR Part 11

21 CFR Part 11: Electronic Records; Electronic Signatures

Cost

€€€€

Complexity

High

Implementation Time

12-18 months

Key Features

Risk-based validation of computerized systems
Secure time-stamped audit trails for changes
Controls for closed and open systems
Unique multi-component electronic signatures
Integration with predicate rule requirements

Detailed Analysis

A comprehensive look at the specific requirements, scope, and impact of each standard.

PIPL Details

What It Is

Personal Information Protection Law (PIPL) is China's first comprehensive national regulation, effective November 1, 2021, with 74 articles across eight chapters. It governs collection, processing, storage, transfer, and deletion of personal information, applying territorially and extraterritorially to foreign entities targeting individuals in China. Adopts a risk-based approach emphasizing consent, minimization, and security, alongside Cybersecurity Law and Data Security Law.

Key Components

Core principles: lawfulness, necessity, minimization, transparency, accountability.
Sensitive personal information (SPI) rules for biometrics, health, minors under 14.
Individual rights: access, correction, deletion, portability, ADM explanations.
Cross-border mechanisms: security assessments, SCCs, certifications. Compliance model mandates impact assessments, DPOs for large handlers, ongoing audits.

Why Organizations Use It

Mandatory for China-exposed firms to avoid fines up to RMB 50M or 5% revenue.
Builds customer trust, enables market access, reduces breach risks.
Strategic advantages: operational resilience, competitive differentiation in digital economy.

Implementation Overview

Phased framework: gap analysis, data mapping, policies, controls, transfers (6-12 months). Applies to multinationals, platforms; requires China representatives, regular audits. (178 words)

FDA 21 CFR Part 11 Details

What It Is

21 CFR Part 11 is a US FDA regulation defining criteria under which electronic records and electronic signatures are trustworthy, reliable, and equivalent to paper records and handwritten signatures. It targets FDA-regulated records created, modified, or maintained electronically under predicate rules. The risk-based approach, clarified in 2003 guidance, narrows scope to relied-upon electronic records.

Key Components

Subpart A: Scope, implementation, definitions (closed/open systems).
Subpart B: Controls for closed (§11.10: validation, audit trails, access) and open (§11.30: encryption) systems; signature manifestation/linking.
Subpart C: Signature requirements (uniqueness, multi-component, non-repudiation). Core principles: authenticity, integrity, accountability. No formal certification; compliance via validation, SOPs.

Why Organizations Use It

Mandatory for life sciences using electronic records (pharma, devices, biotech).
Mitigates enforcement risks, ensures data integrity.
Enables efficient paperless operations, faster inspections.
Builds FDA trust, supports quality systems.

Implementation Overview

Phased: scoping, risk assessment, CSV (URS, IQ/OQ/PQ), vendor governance, training, monitoring. Applies to regulated firms globally; FDA inspections verify compliance. (178 words)

Key Differences

Aspect	PIPL	FDA 21 CFR Part 11
Scope	Personal info collection, processing, transfers	Electronic records/signatures trustworthiness
Industry	All handling Chinese residents' data	Life sciences, pharma, medical devices
Nature	Mandatory national privacy law	Electronic records regulation w/ discretion
Testing	DPIAs, security assessments	System validation, IQ/OQ/PQ
Penalties	RMB 50M or 5% revenue fines	Warning letters, product holds

Scope

PIPL

Personal info collection, processing, transfers

FDA 21 CFR Part 11

Electronic records/signatures trustworthiness

Industry

PIPL

All handling Chinese residents' data

FDA 21 CFR Part 11

Life sciences, pharma, medical devices

Nature

PIPL

Mandatory national privacy law

FDA 21 CFR Part 11

Electronic records regulation w/ discretion

Testing

PIPL

DPIAs, security assessments

FDA 21 CFR Part 11

System validation, IQ/OQ/PQ

Penalties

PIPL

RMB 50M or 5% revenue fines

FDA 21 CFR Part 11

Warning letters, product holds

Frequently Asked Questions

Common questions about PIPL and FDA 21 CFR Part 11

PIPL FAQ

FDA 21 CFR Part 11 FAQ

You Might also be Interested in These Articles...

The NIS2 "FTE Trap": Why 5 Analysts for 24/7 Security is Actually 8 (and Why the Board Needs to Know)

Exposed: NIS2 FTE Trap math shows 5 analysts fail 24/7 coverage due to sickness, training, leave & 2026 churn. Line-by-line breakdown for compliance. Alert your

The Human-AI Synergy: How Modern Compliance Tools Amplify Your Team's Strategic Impact

Unlock human-AI synergy with modern compliance tools. Automate monitoring, cut non-compliance risks 3x, and boost strategic decision-making. Elevate your team's

Decoding Tomorrow's Regulations: How Advanced Compliance Tools Predict and Prepare for Future Shifts

Advanced compliance tools use AI, analytics & real-time monitoring to predict regulatory shifts, cut non-compliance costs 3x, and ensure audit readiness. Stay p

Run Maturity Assessments with GRADUM

Transform your compliance journey with our AI-powered assessment platform

Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

100+ Standards & Regulations

AI-Powered Insights

Collaborative Assessments

Actionable Recommendations

Explore More Comparisons

See how PIPL and FDA 21 CFR Part 11 compare against other standards

Other PIPL Comparisons

Other FDA 21 CFR Part 11 Comparisons

What It Is

Key Components

Core principles: lawfulness, necessity, minimization, transparency, accountability.

Sensitive personal information (SPI) rules for biometrics, health, minors under 14.

Individual rights: access, correction, deletion, portability, ADM explanations.

Cross-border mechanisms: security assessments, SCCs, certifications. Compliance model mandates impact assessments, DPOs for large handlers, ongoing audits.

What It Is

Key Components

Subpart A: Scope, implementation, definitions (closed/open systems).

Subpart B: Controls for closed (§11.10: validation, audit trails, access) and open (§11.30: encryption) systems; signature manifestation/linking.

Subpart C: Signature requirements (uniqueness, multi-component, non-repudiation). Core principles: authenticity, integrity, accountability. No formal certification; compliance via validation, SOPs.

Aspect

PIPL

FDA 21 CFR Part 11

Scope

Personal info collection, processing, transfers

Electronic records/signatures trustworthiness

Industry

All handling Chinese residents' data

Life sciences, pharma, medical devices

Nature

Mandatory national privacy law

Electronic records regulation w/ discretion

Testing

DPIAs, security assessments

System validation, IQ/OQ/PQ

Penalties

RMB 50M or 5% revenue fines

Warning letters, product holds